The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood sugar levels. It calls ...

Biocon Biologics and Civica Inc. not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, has inked a strategic ...

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will ...

Biocon Biologics unit and USA-based Civica Rx, a not-for-profit generic drug and pharmaceutical company, have announced a ...

Biocon Biologics partners with Civica to enhance access to Insulin Aspart in the US, no tech transfer involved.

Number 5: The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat osteoporosis and bone metastases. Number 4: February brought ...

Biocon Biologics on Thursday said it has tied up with not-for-profit generic drug and pharmaceutical firm Civica, Inc to expand access and affordability of Insulin Aspart in the US.

Biocon said that its wholly owned subsidiary, Biocon Biologics announced strategic collaboration agreement with Civica, Inc. to expand access, affordability of Insulin Aspart in the United States.

This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under ...

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), and Civica, Inc. (Civica), a not-for-profit generic drug and ...

Biocon Biologics' own Insulin Aspart drug product for the US is currently under review by the US Food and Drug Administration ...